Organigram (OGI) Competitors $1.56 +0.10 (+6.85%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends OGI vs. KURA, KROS, TYRA, ERAS, CRON, EOLS, DNTH, RAPP, AUTL, and OCSShould you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), Rapport Therapeutics (RAPP), Autolus Therapeutics (AUTL), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Organigram vs. Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Autolus Therapeutics Oculis Kura Oncology (NASDAQ:KURA) and Organigram (NASDAQ:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Do insiders and institutionals have more ownership in KURA or OGI? 34.6% of Organigram shares are owned by institutional investors. 5.5% of Kura Oncology shares are owned by insiders. Comparatively, 0.1% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community believe in KURA or OGI? Kura Oncology received 227 more outperform votes than Organigram when rated by MarketBeat users. However, 70.71% of users gave Organigram an outperform vote while only 69.56% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformKura OncologyOutperform Votes42569.56% Underperform Votes18630.44% OrganigramOutperform Votes19870.71% Underperform Votes8229.29% Does the media refer more to KURA or OGI? In the previous week, Organigram had 13 more articles in the media than Kura Oncology. MarketBeat recorded 15 mentions for Organigram and 2 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.61 beat Organigram's score of 0.02 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Organigram 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate KURA or OGI? Kura Oncology presently has a consensus price target of $29.38, suggesting a potential upside of 226.03%. Given Kura Oncology's higher possible upside, equities analysts clearly believe Kura Oncology is more favorable than Organigram.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00Organigram 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, KURA or OGI? Kura Oncology has higher earnings, but lower revenue than Organigram. Organigram is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura OncologyN/AN/A-$152.63M-$2.36-3.82Organigram$159.84M1.23-$184.34M-$0.38-4.11 Is KURA or OGI more profitable? Kura Oncology has a net margin of 0.00% compared to Organigram's net margin of -45.57%. Organigram's return on equity of -16.76% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Organigram -45.57%-16.76%-14.32% Which has more volatility and risk, KURA or OGI? Kura Oncology has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Organigram has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. SummaryOrganigram beats Kura Oncology on 9 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Organigram News Delivered to You Automatically Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGI vs. The Competition Export to ExcelMetricOrganigramPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.19M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-3.7110.5991.3417.19Price / Sales1.23195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.635.104.794.78Net Income-$184.34M$151.51M$120.07M$225.60M7 Day Performance5.41%-2.14%-1.90%-1.24%1 Month Performance3.65%-3.13%11.43%3.06%1 Year Performance26.83%11.51%30.59%16.50% Organigram Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGIOrganigram0.7685 of 5 stars$1.56+6.8%N/A+27.9%$184.19M$159.84M-3.71860Earnings ReportAnalyst RevisionNews CoverageKURAKura Oncology4.4837 of 5 stars$9.94+3.2%$29.38+195.5%-27.0%$772.93MN/A-4.08142KROSKeros Therapeutics3.2961 of 5 stars$18.80-0.2%$81.33+332.6%-49.6%$761.53M$651,000.00-3.61100High Trading VolumeTYRATyra Biosciences2.0741 of 5 stars$14.93-0.1%$31.00+107.6%+2.0%$755.46MN/A-9.2820Positive NewsERASErasca2.17 of 5 stars$2.60+1.6%$5.90+126.9%+35.8%$735.09MN/A-3.08126News CoveragePositive NewsGap UpCRONCronos Group1.8449 of 5 stars$1.92-0.4%$3.00+56.1%+4.8%$734.86M$87.24M-15.19356News CoverageEOLSEvolus3.8301 of 5 stars$11.53+0.2%$23.00+99.5%+12.5%$730.08M$202.09M-12.73170DNTHDianthus Therapeutics1.3413 of 5 stars$24.31+2.1%$46.43+91.0%+213.2%$719.58M$2.83M-9.5280Analyst ForecastNews CoverageRAPPRapport Therapeutics1.5264 of 5 stars$19.36+3.1%$35.00+80.8%N/A$708.19MN/A0.00N/AAUTLAutolus Therapeutics2.5563 of 5 stars$2.64+6.0%$10.40+293.9%-58.4%$702.48M$1.70M-2.06330OCSOculis1.6453 of 5 stars$17.06-0.2%$29.20+71.2%+57.2%$691.00M$980,000.00-8.852 Related Companies and Tools Related Companies KURA Competitors KROS Competitors TYRA Competitors ERAS Competitors CRON Competitors EOLS Competitors DNTH Competitors RAPP Competitors AUTL Competitors OCS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OGI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OGI Stock Alerts